Valuation Charles River Laboratories International, Inc. Deutsche Boerse AG

Stocks

Real-time Estimate Tradegate 11:38:02 02/10/2026 pm IST			5-day change	1st Jan Change
256.15 ^EUR	-1.97%		-1.28%	+48.27%

30/09	UBS Upgrades Charles River Laboratories International to Buy From Neutral, Adjusts Price Target to $357 From $175	MT
29/09	PMGC Unit Working With Charles River Laboratories for Muscle Health Probiotic Testing	MT

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	18,941	11,138	12,252	9,520	10,023	13,693	-	-
Change	-	-41.2%	10%	-22.3%	5.29%	36.61%	-	-
Enterprise Value (EV) ¹	21,366	13,616	14,622	11,565	11,946	15,846	15,398	15,023
Change	-	-36.28%	7.39%	-20.91%	3.29%	32.65%	-2.83%	-2.44%
P/E	49.4x	23.1x	25.9x	931x	-70x	76.2x	30.6x	27.3x
PBR	7.45x	3.75x	3.41x	2.75x	3.17x	4.57x	3.92x	3.49x
PEG	-	0.9x	-9.44x	-9.5x	0x	-0x	0x	2.3x
Capitalization / Revenue	5.35x	2.8x	2.97x	2.35x	2.5x	3.49x	3.42x	3.23x
EV / Revenue	6.04x	3.42x	3.54x	2.86x	2.98x	4.04x	3.84x	3.55x
EV / EBITDA	24.3x	13.7x	14.4x	11.6x	12.3x	15.5x	13.9x	12.6x
EV / EBIT	28.8x	16.3x	17.4x	14.3x	15x	19.3x	16.8x	14.8x
EV / FCF	40.2x	46.2x	40x	23.1x	23x	49.8x	25.1x	31.6x
FCF Yield	2.49%	2.17%	2.5%	4.34%	4.34%	2.01%	3.99%	3.16%
Dividend per Share ²	-	-	-	-	-	-	-	-
Rate of return	-	-	-	-	-	-	-	-
EPS ²	7.6	9.48	9.22	0.2	-2.91	3.763	9.362	10.5
Distribution rate	-	-	-	-	-	-	-	-
Net sales ¹	3,540	3,976	4,129	4,050	4,015	3,918	4,006	4,234
EBITDA ¹	879.5	990.9	1,013	996.1	971.5	1,020	1,111	1,193
EBIT ¹	742.1	834	838.8	805.9	793.9	821.7	919	1,017
Net income ¹	391	486.2	474.6	10.3	-144.3	164.1	431.1	475.7
Net Debt ¹	2,425	2,477	2,370	2,046	1,923	2,153	1,705	1,330
Reference price ²	375.34	218.92	238.84	186.16	203.66	286.83	286.83	286.83
Nbr of stocks (in thousands)	50,464	50,879	51,297	51,136	49,215	47,739	-	-
Announcement Date	16/02/22	22/02/23	14/02/24	19/02/25	18/02/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
WUXI APPTEC CO., LTD.	21.73x	7.77x	15.61x	1.37%	7.44TCr
ARGENX SE	30.79x	8.87x	27.62x	0.04%	5.93TCr
LONZA GROUP AG	32.79x	5.89x	17.64x	0.99%	4.71TCr
IQVIA HOLDINGS INC.	33.58x	3.26x	14.07x	-.--%	4.29TCr
REVOLUTION MEDICINES, INC.	-21.23x	229.92x	-22.88x	-.--%	4.41TCr
BEONE MEDICINES AG	46.86x	5.42x	29.73x	-.--%	4.08TCr
CELLTRION, INC.	27.79x	7.97x	20.59x	0.41%	3.08TCr
WUXI BIOLOGICS (CAYMAN) INC.	33.94x	7.26x	18.84x	-.--%	2.93TCr
INSMED INCORPORATED	-66.62x	12.77x	-65.09x	-.--%	2.37TCr
Average	15.51x	32.13x	6.24x	0.31%	4.36TCr
Weighted average by Cap.	19.55x	32.23x	10.39x	0.42%